mTOR in Human Diseases

The mechanistic target of rapamycin (mTOR) is a major signaling intermediary that coordinates favorable environmental conditions with cell growth. Indeed, as part of two functionally distinct protein complexes, named mTORC1 and mTORC2, mTOR regulates a variety of cellular processes, including protei...

Full description

Saved in:
Bibliographic Details
:
Year of Publication:2019
Language:English
Physical Description:1 electronic resource (480 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 04907nam-a2201405z--4500
001 993548396004498
005 20231214133329.0
006 m o d
007 cr|mn|---annan
008 202102s2019 xx |||||o ||| 0|eng d
020 |a 3-03921-061-0 
035 |a (CKB)4920000000094826 
035 |a (oapen)https://directory.doabooks.org/handle/20.500.12854/54029 
035 |a (EXLCZ)994920000000094826 
041 0 |a eng 
100 1 |a Dormond, Olivier  |4 auth 
245 1 0 |a mTOR in Human Diseases 
260 |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2019 
300 |a 1 electronic resource (480 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
520 |a The mechanistic target of rapamycin (mTOR) is a major signaling intermediary that coordinates favorable environmental conditions with cell growth. Indeed, as part of two functionally distinct protein complexes, named mTORC1 and mTORC2, mTOR regulates a variety of cellular processes, including protein, lipid, and nucleotide synthesis, as well as autophagy. Over the last two decades, major molecular advances have been made in mTOR signaling and have revealed the complexity of the events implicated in mTOR function and regulation. In parallel, the role of mTOR in diverse pathological conditions has also been identified, including in cancer, hamartoma, neurological, and metabolic diseases. Through a series of articles, this book focuses on the role played by mTOR in cellular processes, metabolism in particular, and highlights a panel of human diseases for which mTOR inhibition provides or might provide benefits. It also addresses future studies needed to further characterize the role of mTOR in selected disorders, which will help design novel therapeutic approaches. It is therefore intended for everyone who has an interest in mTOR biology and its application in human pathologies. 
546 |a English 
653 |a primary cilia 
653 |a neurodegeneration 
653 |a nutrient sensor 
653 |a PI3K 
653 |a transcriptomics 
653 |a phosphorylation 
653 |a metabolic reprogramming 
653 |a autophagy 
653 |a Alzheimer's disease 
653 |a rapalogs 
653 |a liver 
653 |a angiogenesis 
653 |a mTOR complex 
653 |a MBSCs 
653 |a advanced biliary tract cancers 
653 |a Medulloblastoma 
653 |a epithelial to mesenchymal transition 
653 |a AMPK 
653 |a p70S6K 
653 |a lipid metabolism 
653 |a thyroid cancer 
653 |a sodium iodide symporter (NIS)/SLC5A5 
653 |a male fertility 
653 |a anesthesia 
653 |a illumina 
653 |a mTOR inhibitor 
653 |a miRNA 
653 |a Hutchinson-Gilford progeria syndrome (HGPS) 
653 |a eIFs 
653 |a Emery-Dreifuss muscular dystrophy (EDMD) 
653 |a glucose 
653 |a AKT 
653 |a oral cavity squamous cell carcinoma (OSCC) 
653 |a glucose and lipid metabolism 
653 |a cellular signaling 
653 |a aging 
653 |a tumor microenvironment 
653 |a rapamycin 
653 |a leukemia 
653 |a chloral hydrate 
653 |a rapalogues 
653 |a schizophrenia 
653 |a T-cell acute lymphoblastic leukemia 
653 |a senescence 
653 |a lamin A/C 
653 |a neurotoxicity 
653 |a neurodevelopment 
653 |a inhibitor 
653 |a methamphetamine 
653 |a pulmonary fibrosis 
653 |a mTOR 
653 |a mTOR inhibitors 
653 |a combination therapy 
653 |a proteolysis 
653 |a fluid shear stress 
653 |a tumour cachexia 
653 |a biomarkers 
653 |a synapse 
653 |a gluconeogenesis 
653 |a mTOR signal pathway 
653 |a Sertoli cells 
653 |a immunosenescence 
653 |a miRNome 
653 |a protein aggregation 
653 |a senolytics 
653 |a metabolism 
653 |a NGS 
653 |a mTORC2 
653 |a mTORC1 
653 |a metabolic diseases 
653 |a IonTorrent 
653 |a apoptosis 
653 |a dopamine receptor 
653 |a nocodazole 
653 |a microenvironment 
653 |a everolimus 
653 |a acute myeloid leukemia 
653 |a immunotherapy 
653 |a spermatogenesis 
653 |a bone remodeling 
653 |a signalling 
653 |a targeted therapy 
653 |a ageing 
653 |a therapy 
653 |a NVP-BEZ235 
653 |a fructose 
653 |a physical activity 
653 |a laminopathies 
653 |a MC3T3-E1 cells 
653 |a cell signaling 
653 |a microRNA 
653 |a cancer 
653 |a lipolysis 
653 |a melatonin 
653 |a Parkinson's disease 
776 |z 3-03921-060-2 
906 |a BOOK 
ADM |b 2023-12-15 05:50:28 Europe/Vienna  |f system  |c marc21  |a 2019-11-10 04:18:40 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338781390004498&Force_direct=true  |Z 5338781390004498  |b Available  |8 5338781390004498